INVESTOR RELATIONS

Viemed strategy seeks to re-inforce our position as a leader in the US home respiratory health care industry by improving the quality of life for its patients.

Viemed strategy seeks to re-inforce our position as a leader in the US home respiratory health care industry by improving the quality of life for its patients.

QuickFindFind

receive information

IR presentation
and downloads

view

investor
contacts

discover

Investment Highlights

The company is well positioned to pursue sustainable growth and profitability through leveraging its brand awareness, realizing operational synergies, expansion of its product and service offerings and pursing growth into new US states not currently covered by Viemed.

In a very dynamic healthcare landscape, Viemed has managed to build a strong reputation through successful differentiation based on:

Case managers are registered respiratory therapists and assigned to each patient and on call 24/7

Consistent delivery of quality -in service and equipment that requires little servicing

Affordability for patients – low monthly service plans vs large cash outlay for costly at home medical devices and most plan costs covered by Medicare and insurance

Reduction of re-admissions to facilities reduces cost to taxpayers. Viemed patients have a 5.7% re-admission rate, significantly below industry average of 20%

A senior woman in her 70s being cared for at home by her daughter or a nurse, who is helping put an oxygen mask on her face. They are sitting on chairs by a sunny window.

In a very dynamic healthcare landscape, Viemed has managed to build a strong reputation through successful differentiation based on:

Case managers are registered respiratory therapists and assigned to each patient and on call 24/7

Consistent delivery of quality -in service and equipment that requires little servicing

Affordability for patients – low monthly service plans vs large cash outlay for costly at home medical devices and most plan costs covered by Medicare and insurance

Reduction of re-admissions to facilities reduces cost to taxpayers. Viemed patients have a 5.7% re-admission rate, significantly below industry average of 20%

ATTRACTIVE FUNDAMENTALS

back to top

Strong financial performance

Proven clinical results patient outcomes

93% of patients report they breathe better

Patients are 3 times more likely to pass away during 90 days after a Chronic Respiratory failure diagnosis if NIV treatment is not obtained

Reduction of readmissions to facilities reduces cost to payers - currently estimated at approximately $30,000 per patient of annual savings

Viemed patients have on average a 5.4% re-admission rate to hospitals vs a 20% industry standard - a significant saving to hospitals and patients in time and resources

Attractive industry growth opportunity

At the age of 65, patients qualify for Medicare. 10,000 people turn 65 daily for the next 19 years.

Expenditures are expected to grow at a 5.3% CAGR from $46.5 billion to $60.2 billion in 2020

Addressable audience

FINANCIAL REPORTS

back to top

DOWNLOAD

2019

2019 Annual Financial Statements

2019 Q3 Financial Statements

2019 Q2 Financial Statements

2019 Q1 Financial Statements

2019 Q1 MD&A

Notice of Annual Meeting of Shareholders - May 13, 2019

Information Circular 2019

2018

2018 Annual Financial Statements

2018 Year ended MD&A

2018 Q3 Financial Statements

2018 Q3 MD&A

2018 Q2 Financial Statements

2018 Q2 MD&A

2018 Q1 Financial Statements

2018 Q1 MD&A

2017

2017 & 2016 Annual Financial Statements

2017 Year ended MD&A

2017 Q3 Condensed combined interim financial statements

2017 Q3 MD&A

2016

2016 Year ended Combined financial statements

2016 Year ended MD&A

ANALYST COVERAGE

Acumen Capital Finance Partners, Ltd.
Nick Corcoran

Beacon Securities Unlimited
Brooks O’Neil

Lake Street Capital Markets
Doug Cooper

REGULATORY FILINGS

Viemed’s public filings, including news releases, financial reports, management proxy circulars, and annual information forms, are available from The System for Electronic Document Analysis and Retrieval (SEDAR), an electronic filing system for Canadian publicly traded companies and the electronic data gathering, analysis and retrieval (EDGAR), an electronic filing system for US listed companies.

Access all of Viemed’s TSX regulatory filings on SEDAR: https://sedar.com/homepage_en.htm

Access all of Viemed’s NASDAQ regulatory filings on EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001729149&owner=exclude&count=40

NEWS AND EVENTS

back to top

EVENTS

2019

3 March 2020

2019 Year End Earnings - Conference Call

3 March 2020

Transcript: Year End 2019 Earnings Conference Call

5 December 2019

Viemed Healthcare, Inc. - Webcast

5 November 2019

2019 Third Quarter Earnings Conference Call

5 November 2019

Transcript: 2019 Third Quarter Earnings Conference Call

9 August 2019

2019 Second Quarter Earnings Conference Call

9 August 2019

Transcript: 2019 Second Quarter Earnings Conference Call

7 May 2019

2019 First Quarter Earnings Conference Call

7 May 2019

Transcript: 2019 First Quarter Earnings Conference Call

1 April 2019

Spring Investor Summit Conference - Webcast

27 March 2019

Understanding the business and growth path of Viemed - Conference Call

28 February 2019

2018 Year End Earnings - Conference Call

28 February 2019

Transcript: Year End 2018 Earnings Conference Call

2018

5 November 2018

2018 Third Quarter Earnings – Conference Call

5 November 2018

Transcript: 2018 Third Quarter Earnings Conference Call

14 August 2018

2018 Second Quarter Earnings – Conference Call

14 August 2018

Transcript: 2018 Second Quarter Earnings Conference Call

15 June 2018

The Motley Fool Hidden Gems - Interview with CEO and COO

6 June 2018

Proactive Investors Stocktube - Interview with CEO

8 May 2018

2018 Quarterly Earnings – Conference Call

8 May 2018

Transcript: 2018 Quarterly Earnings Conference Call

13 March 2018

2017 Year End Financial Results - Conference Call

22 February 2018

Viemed Healthcare Investor - Webcast

SPECIAL RELEASES

2018

4 October 2018

A Recent KPMG Study Supports that Home Non-invasive Ventilation for COPD Reduces Costs and Hospitalizations

27 July 2018

KPMG Study - A US based cost study analysis assessing the mortality, costs, and hospitalization rates for NIV intervention

IR PRESENTATION AND DOWNLOADS

back to top

PRESENTATION DECK & FACT SHEET

The following information was accurate at the time of posting but may be superseded by subsequent disclosure.

IR PRESENTATION

QUARTERLY AND CONFERENCE CALLS

Viemed hosts quarterly earnings calls. All replays will be posted following calls.

CORPORATE GOVERNANCE

Viemed Healthcare follows and maintains high standards of Corporate Governance. The Board of Directors of Viemed Healthcare believes that good governance practices protect long-term shareholder value and ensure that the Company conducts its activities and operations with integrity and in an ethical manner, geared towards shareholders’ best interests.

Compensation Committee Charter

Charter of the Audit Committee

Corporate Governance and Nominating Committee Charter

Business Corporations Act Articles

Code of Ethics

NASDAQ STOCK INFORMATION

back to top

TSX STOCK INFORMATION

back to top

INVESTOR CONTACT FORM

back to top

SIGN UP HERE FOR AN INVESTOR PACK AND INFORMATION

If you would like to receive a corporate information package or for someone to contact you directly, please complete the form below and we will get back to you shortly:

INVESTOR CONTACTS

back to top